All In Biotech

Drug Trial Radar · NCT04289142

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients

Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients: CODEX Trial

Last checked: Nov 20, 2026Latest source record: Dec 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 2,400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,400

Planned (sponsor's estimate)

Start

Dec 1, 2019

Primary completion

Jul 2028

Study completion Mar 2029

Sponsor

Lead sponsor
Sunnybrook Health Sciences CentreAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
London Health Sciences Centre; University Health Network, Toronto; McMaster University; Canadian Institutes of Health Research (CIHR); The Dana Foundation; Brain Canada; Alzheimer's Association; Hamilton Health Sciences Corporation; University of Saskatchewan; Fraser Health; Providence Health & Services
First posted
Feb 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated. However, many patients have persistent memory impairment for weeks to months after surgery. Cardiac surgery appears to carry the highest risk of postoperative cognitive dysfunction (POCD). These cognitive deficits are associated with increased mortality, prolonged hospital stay and loss of independence. The investigators propose to investigate the role of Dexmedetomidine (DEX) in preventing long-term POCD after cardiac surgery and enhancing early postoperative recovery. It is anticipated that DEX will be the first effective preventative therapy for POCD, improve patient outcomes, and reduce length of stay and healthcare costs.

Conditions

  • Delirium
  • Cognitive Dysfunction
  • Cognition Disorder
  • Neurocognitive Disorders
  • Mental Disorders
  • Confusion
  • Neurobehavioral Manifestations
  • Neurologic Manifestations
  • Nervous System Diseases
  • Signs and Symptoms
  • Dexmedetomidine
  • Hypnotics and Sedatives
  • Central Nervous System Depressants
  • Physiological Effects of Drugs
  • Analgesics, Non-Narcotic
  • Analgesics
  • Molecular Mechanisms of Pharmacological Action

Interventions

  • Dexmedetomidine Hydrochloride GroupDrug

    Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1.2 ug/kg over approximately 20-60 minutes. This will be followed by an infusion at 0.3 ug/kg/h in CVICU for up to 12 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier). Any additional sedatives necessary at the discretion of ICU.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-operative cognitive dysfunctionTime frame: 3 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Royal Columbian Hospital

    Vancouver, British Columbia, Canada · Active not recruiting

  • St. Paul's Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • London Health Sciences

    London, Ontario, Canada · Active not recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • St. Michael's Hospital

    Toronto, Ontario, Canada · Not yet recruiting

  • Toronto General Hospital

    Toronto, Ontario, Canada · Active not recruiting

  • Laval University

    Québec, Quebec, Canada · Recruiting

  • University of Saskatchewan

    Saskatoon, Saskatchewan, Canada · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.